Investment Analysts’ Recent Ratings Updates for Charles River Laboratories International (CRL)

Posted by Renee Jackson on Aug 10th, 2026

Several analysts have recently updated their ratings and price targets for Charles River Laboratories International (NYSE: CRL):

8/7/2026 – Charles River Laboratories International had its price target raised by Morgan Stanley from $260.00 to $300.00. They now have an “overweight” rating on the stock.
8/6/2026 – Charles River Laboratories International was given a new $291.00 price target by Robert W. Baird.
8/6/2026 – Charles River Laboratories International had its price target raised by Royal Bank Of Canada from $215.00 to $282.00. They now have an “outperform” rating on the stock.
8/6/2026 – Charles River Laboratories International was upgraded by JPMorgan Chase & Co. from “neutral” to “overweight”. They now have a $310.00 price target on the stock, up from $180.00.
8/5/2026 – Charles River Laboratories International had its “overweight” rating reaffirmed by Barclays PLC. They now have a $300.00 price target on the stock.
8/5/2026 – Charles River Laboratories International had its “outperform” rating reaffirmed by Evercore Inc.
7/20/2026 – Charles River Laboratories International was downgraded by CLSA from “outperform” to “hold”. They now have a $219.00 price target on the stock.
7/13/2026 – Charles River Laboratories International had its price target raised by Mizuho from $192.00 to $230.00. They now have a “neutral” rating on the stock.
7/9/2026 – Charles River Laboratories International had its price target raised by Morgan Stanley from $220.00 to $260.00. They now have an “overweight” rating on the stock.
7/8/2026 – Charles River Laboratories International had its “buy” rating reaffirmed by Citigroup Inc..
7/1/2026 – Charles River Laboratories International was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
7/1/2026 – Charles River Laboratories International was given a new $250.00 price target by Sanford C. Bernstein.
7/1/2026 – Charles River Laboratories International was given a new $250.00 price target by BNP Paribas Exane.
6/17/2026 – Charles River Laboratories International was upgraded by Morgan Stanley from “equal weight” to “overweight”. They now have a $220.00 price target on the stock, up from $185.00.
6/16/2026 – Charles River Laboratories International was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,046 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total value of $1,327,098.00. Following the completion of the sale, the executive vice president owned 4,807 shares of the company’s stock, valued at $1,264,241. The trade was a 51.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James C. Foster sold 75,000 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the sale, the director owned 31,596 shares of the company’s stock, valued at approximately $7,109,100. This trade represents a 70.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.